KRAS G12D–Mutated Metastatic Pancreatic Cancer: Zoldonrasib Plus Chemotherapy

An investigational targeted therapy designed to block one of the most common genetic drivers of pancreatic cancer has shown high rates of activity when combined with standard first-line chemotherapy, according to early findings presented at the ESMO Gastrointestinal Cancers Congress 2026.

Advanced Gastric or GEJ Cancer: First-Line Disitamab Vedotin, Tislelizumab, and S-1

A Chinese phase II trial investigated the first-line regimen in patients with HER2-overexpressing advanced gastric/gastroesophageal junction (GEJ) adenocarcinoma.

ctDNA Status May Predict Benefit From Adjuvant Chemotherapy After Resection of Colorectal Liver Metastases

ctDNA for molecular residual disease tracking could help identify patients with colorectal cancer and liver metastases who are most likely to benefit from adjuvant chemotherapy after surgery, according to findings from an overall survival analysis of the phase II GALAXY study presented at the ESMO Gastrointestinal Cancers Congress 2026.